Rigosertib for RDEB-SCC

Key facts

Sponsor

Prof. Johann Bauer

Principal Investigator

Johann W Bauer, Prof., MD

Department of Dermatology, Paracelsus Medical University, Salzburger Landeskliniken

Intervention

Rigosertib Oral Capsules / Rigosertib Intravenous(drug)

Enrollment

2 enrolled

Eligibility

18-79 years · All sexes

Timeline

2021 – 2025

Study locations (1)

• EB House Austria/Dept. of Dermatology University Hospital, Salzburg, Salzburg, Austria

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06594393
  A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
  Xinnate AB
• RECRUITINGPHASE1, PHASE2NCT07193134
  GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment
  CHU de Quebec-Universite Laval
• RECRUITINGPHASE1, PHASE2NCT06834035
  Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
  M. Peter Marinkovich
• RECRUITINGPHASE3NCT07016750
  A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
  Krystal Biotech, Inc.
• RECRUITINGPHASE3NCT06917690
  A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
  Chiesi Farmaceutici S.p.A.
• ACTIVE NOT RECRUITINGPHASE3NCT06892639
  Evaluation of D-Fi for the Treatment of Wounds Due to DEB
  Castle Creek Biosciences, LLC.
• RECRUITINGNCT06423573
  A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
  Amryt Pharma
• RECRUITINGPHASE1, PHASE2NCT04173650
  MSC EVs in Dystrophic Epidermolysis Bullosa
  Aegle Therapeutics

See all trials for Dystrophic epidermolysis bullosa →